SEATTLE -- Surgery for pancreatic neuroendocrine tumors (pNETs) significantly improved survival for all patients except those with the earliest-stage disease, a retrospective review of 4,700 patients ...

SEATTLE -- Patients with small (<1 cm) pancreatic neuroendocrine tumors (pNETs) had a 5-year survival of 100% with surveillance, data from a large retrospective study showed. Surgery for small pNETs ...

Neuroendocrine tumors (NETs) are rare cancers that can arise in a number of different organs, particularly the gastrointestinal tract, lungs, and pancreas. The clinical course of these tumors can vary ...

Effect of BPM 31510 on survival outcomes when used in combination with gemcitabine in a preclinical model of pancreatic cancer. Serum levels of macrophage inhibitory cytokine-1 (MIC1) and matrix ...

Two distinct subtypes discovered, each with dramatically different risks of recurrence Patients with more aggressive subtype can be monitored vigilantly for recurrence and possible treatment, while ...

Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors – known as pNETs – that have dramatically different risks of recurrence following surgical treatment [or surgery].

To learn more about pNETs and how they differ from other types of pancreatic cancer, we spoke with Xavier Keutgen, MD, the director of University of Chicago Neuroendocrine Tumor Program and one of the ...

Survival trends in chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC) and the effect of yttrium-90 (Y90) radioembolization: SEER versus tertiary cancer center. Second-line gemcitabine ...

Treatment options for pancreatic neuroendocrine tumors (PNETs) have expanded considerably based on data from pivotal trials such as RADIANT-3 (NCT00510068), 1 Study A6181111 (NCT0 ...

Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors—known as pNETs—that have dramatically different risks of recurrence following surgical treatment [or surgery]. The ...